Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Entrada Therapeutics (TRDA) EPS (Basic): 2022-2025

Historic EPS (Basic) for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to -$1.06.

  • Entrada Therapeutics' EPS (Basic) fell 202.86% to -$1.06 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.55, marking a year-over-year decrease of 252.69%. This contributed to the annual value of $1.76 for FY2024, which is 980.00% up from last year.
  • As of Q3 2025, Entrada Therapeutics' EPS (Basic) stood at -$1.06, which was down 1.92% from -$1.04 recorded in Q2 2025.
  • Over the past 5 years, Entrada Therapeutics' EPS (Basic) peaked at $1.61 during Q2 2024, and registered a low of -$1.06 during Q3 2025.
  • Over the past 3 years, Entrada Therapeutics' median EPS (Basic) value was -$0.29 (recorded in 2023), while the average stood at -$0.07.
  • As far as peak fluctuations go, Entrada Therapeutics' EPS (Basic) soared by 433.33% in 2024, and later tumbled by 202.86% in 2025.
  • Entrada Therapeutics' EPS (Basic) (Quarterly) stood at -$0.78 in 2022, then soared by 62.82% to -$0.29 in 2023, then spiked by 89.66% to -$0.03 in 2024, then crashed by 202.86% to -$1.06 in 2025.
  • Its EPS (Basic) stands at -$1.06 for Q3 2025, versus -$1.04 for Q2 2025 and -$0.42 for Q1 2025.